Drug Profile

ADG 152

Alternative Names: ADG-152

Latest Information Update: 18 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adagene
Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

13 Dec 2021 Pharmacodynamics and pharmacokinetics data from a preclinical study in Cancer released by Adagene
11 Dec 2021 Pharmacodynamics data from preclinical trial in Cancer presented at the 63^rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
19 Nov 2021 Adagene has patents pending for bispecific T cell engager targeting CD3 worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com